Loading clinical trials...
Loading clinical trials...
DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy
Conditions
Interventions
Anifrolumab
Locations
19
Italy
Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato
Monserrato, CA, Italy
Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna
Cona, Ferrara, Italy
IRCCS Humanitas Research Hospital
Rozzano, Milano, Italy
AOU Ospedali Riuniti di Ancona - Presidio Torrette
Ancona, Italy
Azienda Ospedaliero-Universitaria Policlinico di Bari
Bari, Italy
ASST Spedali Civili di Brescia
Brescia, Italy
Start Date
December 31, 2025
Primary Completion Date
September 30, 2028
Completion Date
September 30, 2028
Last Updated
April 3, 2026
NCT07015983
NCT07438496
NCT06673043
NCT05648500
NCT06881290
NCT06316791
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions